Final Report to DWI September 2020 Personal Care Products and Domestic Cleaning Products – Toxicological Assessment of Prioritised List of Chemicals (Ref: DWI 70/2/331) FINAL REPORT Report to Defra/DWI IEH Consulting Ltd.|September 2020 Final Report to DWI September 2020 PCPs and DCPs – toxicological assessment of prioritised list of chemicals A Report to DWI by IEH Consulting Ltd. Disclaimer The views expressed in this report are those of the authors alone, representing their expert opinion based on the review of the available information and their understanding drawn from publications identified from targeted literature searches. Prepared by: Ruth Bevan, Sarah Bull Reviewed by: Camilla Alexander-White, Paul Rumsby Edited by: Paul Harrison September 2020 Final Report to DWI September 2020 Contents Contents Abbreviations ............................................................................................................................. 8 Executive Summary .................................................................................................................... 9 1.0 Introduction ....................................................................................................................... 11 1.1 Project Background ............................................................................................................ 11 1.2 Personal Care Products ...................................................................................................... 11 1.3 Domestic Cleaning Products .............................................................................................. 11 1.4 Selection of PCPs and DCPs of concern ............................................................................. 12 1.5 Aims and objectives ........................................................................................................... 13 2.0 Methodology ...................................................................................................................... 13 2.1 Literature search ................................................................................................................ 13 2.2 Screening of literature ....................................................................................................... 13 2.3 Risk assessment process .................................................................................................... 14 2.3.1 Hazard identification ............................................................................................... 14 2.3.2 Dose-response assessment ..................................................................................... 14 2.3.3 Exposure assessment .............................................................................................. 15 2.3.4 Risk characterisation ............................................................................................... 15 General references .................................................................................................................. 16 3.0 Results ................................................................................................................................ 18 3.1 Identification of data ......................................................................................................... 18 3.2 Human health risk assessments for exposure via drinking water ..................................... 19 Section A: 1,2,3-benzotriazole ................................................................................................. 20 Section A1.0 Chemical identification, use and potential human exposure ............................. 20 Section A1.1 Reasons for consideration .......................................................................... 20 Section A1.2 Identification and physicochemical properties. ......................................... 20 Section A1.3 Hazard classifications .................................................................................. 20 Section A1.4 Occurrence, production and use. ............................................................... 20 Section A1.5 Human exposure ......................................................................................... 21 Section A2.0 Human relevant health effects ........................................................................... 21 Section A2.1 Toxicokinetics.............................................................................................. 21 Section A2.2 Acute toxicity .............................................................................................. 22 Section A2.3 Repeat dose toxicity ................................................................................... 22 Final Report to DWI September 2020 Section A3.0 Identification of relevant point(s) of departure for use in risk assessment ....... 27 Section A3.1 Critical endpoint for human health risk assessment purposes .................. 27 Section A3.2 Current guideline values ............................................................................. 30 Section A3.3 Identification of POD to be used for the risk assessment .......................... 30 Section A4.0 – Drinking water risk assessment ....................................................................... 30 References ............................................................................................................................... 31 Section B: 1H-benzotriazole, 4(or 5)-methyl- .......................................................................... 33 Section B1.0 Chemical identification, use and potential human exposure ............................. 33 Section B1.1 Reasons for consideration .......................................................................... 33 Section B1.2 Identification and physicochemical properties. ......................................... 33 Section B1.3 Hazard classifications .................................................................................. 33 Section B1.4 Occurrence, production and use. ............................................................... 33 Section B1.5 Human exposure ......................................................................................... 34 Section B2.0 Human relevant health effects ........................................................................... 35 Section B2.1 Toxicokinetics .............................................................................................. 35 Section B2.2 Acute toxicity .............................................................................................. 35 Section B2.3 Repeat dose toxicity.................................................................................... 35 Section B3.0 Identification of relevant point(s) of departure for use in risk assessment ....... 38 Section B3.1 Critical endpoint for human health risk assessment purposes .................. 38 Section B3.2 Current health-based guidance values ....................................................... 41 Section B3.3 Identification of POD to be used for the risk assessment. ......................... 41 Section B4.0 Drinking water risk assessment .......................................................................... 41 References ............................................................................................................................... 42 Section C: (1-hydroxyethylidene) diphosphonic acid (HEDP) .................................................. 43 Section C1.0 Chemical identification, use and potential human exposure ............................. 43 Section C1.1 Reasons for consideration .......................................................................... 43 Section C1.2 Identification and physicochemical properties. ......................................... 43 Section C1.3 Hazard classifications .................................................................................. 44 Section C1.4 Occurrence, production and use. ............................................................... 44 Section C1.5 Human exposure ......................................................................................... 44 Section C2.0 Human relevant health effects ........................................................................... 44 Section C2.1 Toxicokinetics .............................................................................................. 44 Section C2.2 Acute toxicity .............................................................................................. 45 Section C2.3 Repeat dose toxicity .................................................................................... 45 Final Report to DWI September 2020 Section C3.0 Identification of relevant point(s) of departure for use in risk assessment ....... 52 Section C3.1 Critical endpoints for human health risk assessment purposes ................. 52 Section C3.2 Current health-based guidance values ....................................................... 55 Section C3.3 Identification of POD to be used for the risk assessment .......................... 55 Section C4.0 Drinking water risk assessment .......................................................................... 55 References ............................................................................................................................... 56 Section D: Diethylenetriamine penta(methylene phosphonic acid) (DTPMP) ........................ 57 Section D1.0 Chemical identification, use and potential human exposure